title: Novel formulation of cytarabine and daunorubicin: A new hope in AML treatment.
abstract: Acute myeloid leukemia (AML) treatment has always been a challenge to the treating physician. Continuous efforts are being made to improve treatment outcomes in AML. CPX-351 is a pharmacologic advancement in this direction. It is a liposomal fixed drug combination of cytarabine and daunorubicin. Early studies indicate that it will play a big role in AML treatment. This is a short review about this drug.
authors.affiliation: Department of Medicine, Leukemia/BMT Division, Vancouver General Hospital, Vancouver, British Columbia, Canada.
authors.forename: Lalit S
authors.initials: LS
authors.lastname: Raut
keywords: Acute myeloid leukemia; CPX-351; cytarabine; daunorubicin; liposomes
references.citation: Leuk Res. 2009 Jan;33(1):129-39
references.pmid: 18676016
references.citation: Adv Enzyme Regul. 1984;22:27-55
references.pmid: 6382953
references.citation: J Clin Oncol. 2011 Mar 10;29(8):979-85
references.pmid: 21282541
references.citation: Mol Cancer Ther. 2006 Jul;5(7):1854-63
references.pmid: 16891472
references.citation: Mol Interv. 2007 Aug;7(4):216-23
references.pmid: 17827442